Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BMS-561392. Bristol-Myers Squibb.

Martin Grootveld1, Michael F McDermott

  • 1Department of Diabetes and Metabolic Medicine, Queen Mary, University of London, Mile End Road, London E1 1BB, UK.

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2003
PubMed
Summary

Bristol-Myers Squibb is developing BMS-561392, a novel inhibitor targeting tumor necrosis factor-alpha (TNF alpha) converting enzyme. This drug shows potential for treating inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacy Undergraduate Education: Can Student Primary Care Placements Add Value to Learning and Teaching?

Clinics and practice·2026
Same author

High-Resolution <sup>1</sup>H NMR Investigation of the Speciation Status of Nickel(II) and Copper(II) Ions in a Cell Culture Medium: Relevance to Their Toxicological Actions.

Molecules (Basel, Switzerland)·2026
Same author

Assessing the effects of thermo-oxidation and naturally-occurring trace metal ions on the peroxidative susceptibilities of unrefined and refined sunflower oils: An 1H NMR-coupled chemometrics study.

Food research international (Ottawa, Ont.)·2025
Same author

Enhancing Process Control and Quality in Amorphous Solid Dispersions Using In-Line UV-Vis Monitoring of L* as a Real-Time Response.

Pharmaceutics·2025
Same author

Photobiomodulation LED Devices for Home Use: Design, Function and Potential: A Pilot Study.

Dentistry journal·2025
Same author

Speciation of Potentially Carcinogenic Trace Nickel(II) Ion Levels in Human Saliva: A Sequential Metabolomics-Facilitated High-Field <sup>1</sup>H NMR Investigation.

Metabolites·2025

Area of Science:

  • Pharmacology
  • Immunology
  • Drug Development

Background:

  • Overproduction of tumor necrosis factor-alpha (TNF alpha) is implicated in various inflammatory diseases.
  • Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are conditions associated with elevated TNF alpha levels.

Purpose of the Study:

  • To investigate the potential of BMS-561392 (DPC-333) as a therapeutic agent.
  • To evaluate BMS-561392 for treating diseases characterized by TNF alpha overproduction.

Main Methods:

  • Development of BMS-561392, a TNF alpha converting enzyme inhibitor.
  • Initiation of a Phase IIa clinical trial in rheumatoid arthritis patients.

Main Results:

  • BMS-561392 was under investigation for rheumatoid arthritis by April 2001.
  • By October 2002, its potential for treating inflammatory bowel disease was also being explored.

Conclusions:

  • BMS-561392 is a promising drug candidate for inflammatory diseases.
  • Further investigation into BMS-561392 for RA and IBD is warranted.

Related Experiment Videos